By merging precision genetic engineering with the scalability of nanomedicine and the predictive power of AI, scientists are reshaping the future of human health.
- Why A Cell Therapy CEO Waited Until Phase III To Outsource
- Field Notes: APEC RHSC's Workshop On ATMP Development And Evaluation
- U.S. Pharma Tariffs And MFN Become Law After April 2 Update
- How To Implement Post-Approval Changes On A Global Level
- March 2026 — CDMO Opportunities And Threats Report
- Target Selection Drives The Future Of CAR T Therapy In Solid Tumors
- Mastering Biotech's Insourcing/Outsourcing Trade-Offs
- From Principles To Practice: Building Quality Into Generative AI-Assisted Pharma Operations
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Cell Collection Basics For The Transplant And CGT Industries
Breakthroughs in CAR T-cell and stem cell therapies depend on mastering cellular collection. Understanding these fundamentals is vital for advancing treatment efficacy and patient outcomes.
-
Accelerated LVV Manufacturing Enabled By Platform Excellence
Discover how a manufacturing platform enabled the rapid production of lentiviral vector in eight months. Learn the strategy used to balance speed, risk mitigation, and the highest quality standards.
-
The True ROI Of Decentralized Clinical Trials
Gain a greater understanding of how the right DCT solution, or combination of solutions, coupled with clear metrics and expert guidance on execution, can demonstrate tangible, quantitative ROI in clinical trials.
-
A Human-Relevant Model Of The Liver Sinusoid
This organ-on-a-chip model minimizes drug absorption while maintaining the essential architecture. Explore the specifications of this product engineered to model the human liver.
-
The Role Of Peptones In Boosting Monoclonal Antibody Production
Peptones have become a key tool in CHO cell bioprocessing, enhancing monoclonal antibody yield and quality.
-
What FDA CRLs Reveal About Method Validation
FDA rejection letters reveal validation failures are structural, not technical. Weak lifecycle oversight, robustness, and documentation continue to delay approvals despite clear guidance.
-
Enhance Access And Improve Retention In Rare Disease Trials With HTS
Home Trial Support (HTS) provides a solution to improving participant recruitment and retention during musculoskeletal studies.
-
Multiplex Imaging
Explore recombinant antibody reagents that support the imaging of key targets within the TME and offer flexible solutions across various platforms to improve patient outcomes.
-
Collaborative Variability Reduction In Cell Culture Media
Variability reduction programs improve biomanufacturing by controlling raw‑material complexity, optimizing critical attributes, and boosting productivity through data‑driven partnerships.
-
Explore A High-Performing Basal Medium And Feed Pairing
A customer sought to replace a chemically defined CHO medium with a more efficient medium and feed pairing strategy in bioreactors.
NEWSLETTER ARCHIVE
- 04.20.26 -- Why A Cell Therapy CEO Waited Until Phase III To Outsource
- 04.17.26 -- Large Molecule Capacity Powering Cell & Gene Therapies
- 04.17.26 -- Building Smarter Cell Therapies With AI And Synthetic Biology
- 04.16.26 -- Cell & Gene Capabilities That You Need to Know
- 04.16.26 -- Prioritizing Quality, Fit, And Supplier Reliability In CGT Materials
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections